EndoGene.Bio decodes epigenetics in menstrual blood to unlock patient tissue-level insights for therapeutic discovery and diagnostics.
EndoGene.Bio has raised $3.1M in total funding. The most recent round was Pre-Seed. The last funding was announced in June 2023.
EndoGene.Bio's investors include Entrepreneurs First, Atomico, Frontline Ventures, Zubi Capital.
EndoGene.Bio is headquartered in Paris, France.
EndoGene.Bio decodes epigenetics in menstrual blood to unlock patient tissue-level insights for therapeutic discovery and diagnostics.
EndoGene.Bio is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EndoGene.Bio — Funding & Investors." VCBacked, June 1, 2023, https://www.vcbacked.co/company/endogenebio. Accessed July 19, 2026.
VCBacked. (2023). EndoGene.Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/endogenebio
{{cite web |title=EndoGene.Bio — Funding & Investors |url=https://www.vcbacked.co/company/endogenebio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated